Development of a novel live attenuated African swine fever vaccine based on deletion of gene I177L

A recombinant ASFV-GΔI177L vaccine, developed by deleting the I177L gene, provides effective protection against African Swine Fever by inducing immunity and preventing disease symptoms in pigs, addressing the lack of a commercially available vaccine.

JP7591043B2Active Publication Date: 2024-11-27US SEC AGRI
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
JP2022518213
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2019-09-24
Filing Date
2020-03-13
Publication Date
2024-11-27
Estimated Expiration
2040-03-13

Smart Images

  • Figure 0007591043000003
    Figure 0007591043000003
  • Figure 0007591043000004
    Figure 0007591043000004
  • Figure 0007591043000005
    Figure 0007591043000005
Patent Text Reader

Abstract

Details are provided regarding the construction of a recombinant live-attenuated African swine fever virus (ASFV) vaccine to prevent ASF caused by various ASFV strains, such as the highly virulent Georgia 2007 isolate ("ASFV-G"). An exemplary vaccine comprises the ASFV-GΔI177L modified virus, which is a recombinant ASFV-G that has been modified by deleting a portion of the I177L ORF, rendering the I177L gene non-functional.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] FIELD OF THEINVENTION

[0002] This disclosure provides details regarding the construction of a recombinant live attenuated ASFV vaccine for the prevention of ASF caused by various strains of African Swine Fever Virus (ASFV), such as the highly virulent Georgia 2007 isolate ("ASFV-G"). An exemplary vaccine includes the ASFV-GΔI1771 modified virus, which is a recombinant ASFV-G modified by deleting a portion of the I177L ORF to render the I177L gene non-functional. [Background technology]

[0003] background

[0004] African Swine Fever (ASF) is a contagious viral disease of pigs. The causative virus, ASF virus (ASFV), is a large enveloped virus containing a double-stranded DNA genome of approximately 190 kilobase pairs. ASFV shares aspects of genome structure and replication strategy with other large double-stranded DNA viruses, including Poxviridae, Iridoviridae and Phycodnaviridae (Costard et al, Phil. Trans. Royal Soc. B, (2009) 364:2683-96). ASFV infection in domestic pigs is frequently fatal and is characterized by fever, hemorrhage, ataxia and severe depression. However, the course of infection is variable, ranging from highly lethal to subclinical, depending on the nature of the host and the particular virus strain (Tulman et al, Curr. Top. Microbial. Immunol. (2009) 328:43-87).

[0005] It is now endemic in more than 20 countries in sub-Saharan Africa. In Europe, ASF remains endemic in Sardinia (Italy) and new outbreaks have been declared in the Caucasus since 2007, affecting Georgia, Armenia, Azerbaijan, and Russia. Recently, outbreaks have been reported in Ukraine, Belarus, Lithuania, Latvia, and Poland, affecting both wild pigs and pig farms. In 2018-2019, ASF spread to China, Mongolia, Vietnam, Cambodia, and North Korea (both in wild pigs and pig farms). In 2019, ASF also spread to wild pig populations in Belgium, where ASF is currently only limited to small areas. Recent ASF outbreaks pose a risk of further spread to neighbouring countries. The epidemic parent virus, ASFV Georgia 2007 / 1, is a highly pathogenic isolate belonging to genotype II (Chapman et al, Emerging Infect. Dis. (2011) 17:599-605) that is responsible for all recent outbreaks in Asia and Europe, with the outbreak viruses sharing more than 90% similarity to the parent strain.

[0006] Currently, there is no commercially available vaccine available for ASF, and disease outbreaks are controlled by animal quarantine and slaughter. Attempts to vaccinate animals with infected cell extracts, supernatants of infected porcine peripheral blood leukocytes, purified inactivated virions, infected macrophages fixed with glutaraldehyde, or infected alveolar macrophages treated with detergent have failed to induce protective immunity (Coggins, L., Prag. Med. Viral. (1974) 18:48-63; Forman et al, Arch. Viral., (1982) 74:91-100; Kihm et al, (1987) In: African Swine Fever, Becker, Y. (ed), Martinus Nijhoff, Boston, pp 127-44; Mebus, CA, Adv. Virus Res., (1988) 35:251-69). Homologous protective immunity develops in pigs that survive viral infection. Pigs that survive acute infection with moderately virulent or attenuated ASFV variants develop long-term resistance to homologous viral challenge, but rarely to heterologous viruses (Hamdy and Dardiri, Am. J. Vet. Res. (1984) 45:711-14; Ruiz-Gonzalvo et al, (1981) In: FAO / CEC Expert Consultation in ASF Research, Wilkinson, PJ (ed), Rome, pp 206-16). Herein, we report the development of a recombinant vaccine that contains a partial deletion of the I177L gene from the ASFV-G genome. Vaccination of pigs with this virus protected them from ASF outbreaks. As there is currently no ASFV vaccine available, the development of a vaccine that can induce protection against lethal manifestations of the disease is of great interest. Summary of the Invention

[0007] The present disclosure provides genetically modified viruses, which comprise a viral genome that is at least 99% identical to SEQ ID NO: 2. In certain embodiments, the viral genome comprises SEQ ID NO:2.

[0008] Also provided herein is a vaccine composition against African Swine Fever Virus (ASFV), comprising a genetically modified virus comprising a viral genome that is at least 99% identical to SEQ ID NO: 2. In some embodiments, the ASFV strain is the ASFV-Georgia 2007 isolate.

[0009] Further provided herein is a method for protecting pigs from ASFV, comprising administering to the pig a live attenuated vaccine comprising a genetically modified virus, wherein the virus comprises a viral genome that is at least 99% identical to SEQ ID NO:2, in an amount effective to protect pigs from clinical ASFV disease. In some embodiments, the ASFV is ASFV-G. In certain embodiments, the amount effective to protect pigs from clinical ASFV disease is greater than or equal to 10 2 ~10 6 HAD 50 It is a vaccine containing a genetically modified virus.

[0010] A further embodiment provided herein is a recombinant ASFV mutant virus comprising a synthetic mutation in the I177L open reading frame or in a regulatory element controlling expression of the I177L protein resulting in a non-functional genomic I177L gene. In a particular embodiment, the synthetic mutation is a deletion mutation resulting in a deletion of one or more nucleotides at positions 174471-175004 of SEQ ID NO:1. In other embodiments, the synthetic mutation is a frameshift mutation, an insertion mutation, a nonsense mutation of one or more nucleotides at positions 174471-175004 of SEQ ID NO:1. In an embodiment, the mutant ASFV is an ASFV-Georgia isolate. In a particular embodiment, the mutant ASFV comprises a genome that is at least 95% identical, or at least 99% identical to SEQ ID NO:2.

[0011] Further provided herein is a vaccine composition against ASFV-G comprising a recombinant ASFV mutant virus that contains a synthetic mutation in the I177L open reading frame or in a regulatory element that controls expression of the I177L protein, resulting in a non-functional genomic I177L gene.

[0012] Also provided herein is a method for protecting pigs from ASFV, comprising administering to the pig a live attenuated vaccine comprising a recombinant ASFV mutant virus comprising a synthetic mutation in the I177L open reading frame or in a regulatory element controlling expression of the I177L protein resulting in a non-functional genomic I177L gene, in an amount effective to protect said pig from clinical ASFV disease. In certain embodiments, the ASFV is ASFV-G. In some embodiments, an amount effective to protect pigs from clinical ASFV disease is greater than or equal to 10 2 ~10 6 HAD 50 It is a vaccine containing a genetically modified virus.

[0013] INCORPORATION BY REFERENCE All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference.

[0014] The patent application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee.

[0015] The novel features of the invention are set forth with particularity in the claims. The features and advantages of the invention will be referenced in the following detailed description and the accompanying drawings. [Brief description of the drawings]

[0016] [Figure 1] FIG. 1 provides a diagram of the cassettes used to generate the ASFV-GΔI177L recombinant mutant virus.

[0017] [Diagram 2] Figure 2 provides a graphical representation of the in vitro growth characteristics of ASFV-G-ΔI177L and parental ASFV-G. Primary porcine macrophage cell cultures were infected with each virus (MOI=0.01) and virus yields were titrated at the indicated times post-infection. Data represent the mean from three independent experiments. Virus detection sensitivity ≥ 1.8 log10 HAD50 / ml.

[0018] [Diagram 3] Figure 3 provides a graphical representation of viremia titers detected in pigs inoculated IM with either 102 HAD50 of ASFV-G-ΔI177L or 102 HAD50 of ASFV-G. Each curve represents values ​​from an individual animal in each group. Virus detection sensitivity > log10 1.8 log10 TCID50 / ml.

[0019] [Figure 4]Figure 4 graphically depicts the kinetics of body temperature values ​​in pigs inoculated IM with either ASFV-G-ΔI177L at 102, 104, or 106 HAD50 (closed symbols), mock inoculated (background, shown in red), or ASFV-G at 102 HAD50 (open symbols) (left panel) and after challenge with ASFV-G at 102 HAD50 (right panel). Each curve represents the values ​​of an individual animal in each group.

[0020] [Diagram 5] Figure 5 provides a graphical representation of viremia titers detected in pigs inoculated IM with either ASFV-G-ΔI177L at 102, 104, or 106 HAD50 or ASFV-G at 102 HAD50. Viremia following challenge with ASFV-G at 102 HAD50. Each curve represents values ​​from an individual animal in each group. Virus detection sensitivity >= log10 1.8 TCID50 / ml.

[0021] [Figure 6] Figure 6 provides a graphical representation of anti-ASFV antibody (IgM-mediated is shown in the left column panels and IgG-mediated is shown in the right column panels) titers detected by ELISA in pigs inoculated IM with either 102, 104, or 106 HAD50 of ASFV-G-ΔI177L. IgM-mediated antibody responses. Each curve represents values ​​from an individual animal in each group. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0022] African swine fever virus (ASFV) is the causative agent of a contagious and often fatal viral disease of domestic pigs that has a significant economic impact on the swine industry. Control of African swine fever (ASF) is hampered by the lack of availability of a vaccine. Experimental vaccines derived from naturally occurring, cell culture adapted, or genetically modified live attenuated ASFV have been previously reported. However, none of these vaccines have been developed for commercial use. Here, we report the discovery that deletion of a previously uncharacterized gene, I177L, from a highly virulent ASFV isolate, the Georgia isolate (ASFV-G), results in its complete attenuation in pigs. Animals inoculated intramuscularly (IM) with a virus lacking a functional I177L gene (e.g., the specific ASFV-G-ΔI177L mutant described herein) remain clinically normal during a 28-day observation period. Importantly, ASFV-G-ΔI177L-infected animals were protected when challenged with the virulent parental ASFV-G.

[0023] Preferred embodiments of the present invention are shown and described herein. It will be apparent to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes, and substitutions will occur to those skilled in the art without departing from the invention. Various alternatives to the embodiments of the invention described herein can be used in the practice of the invention. It is intended that the following claims define the scope of the invention, and that methods and structures within the scope of these claims and their equivalents be covered thereby.

[0024] The technical and scientific terms used herein have the meanings that are commonly understood by those skilled in the art to which the present invention pertains, unless otherwise defined. Various materials and methods known to those skilled in the art are referred to herein. Standard references that describe the general principles of recombinant DNA technology include Sambrook et al., "Molecular Cloning: A Laboratory Manual", 2d ed., Cold Spring Harbor Laboratory Press, Plainview, NY, 1989; Kaufman et al., eds., "Handbook of Molecular and Cellular Methods in Biology and Medicine", CRC Press, Boca Raton, 1995; and McPherson, ed., "Directed Mutagenesis: A Practical Approach", IRL Press, Oxford, 1991.

[0025] Any suitable material and / or method known to those skilled in the art can be utilized in carrying out the present invention. The material and / or method for carrying out the present invention is described. The materials, reagents, etc. referred to in the following description and examples are available from commercial sources unless otherwise stated. The present invention teaches methods and describes tools for producing genetically modified strains of ASFV.

[0026] As used in the specification and claims, the use of the singular forms "a," "an," and "the" includes plural references unless the context clearly dictates otherwise.

[0027] As used herein, the terms "isolated," "purified," or "biologically pure" refer to material that is substantially or essentially free from components that normally accompany the referenced material in its natural state.

[0028] The term "about" is defined as plus or minus 10% of the stated value, for example, about 1.0 g means 0.9 g to 1.1 g, and all values ​​within that range, whether or not specifically stated.

[0029] The term "nucleic acid consisting essentially of" and grammatical variations thereof refer to a nucleic acid that differs from a reference nucleic acid sequence by 20 or fewer nucleic acid residues and that also performs the function of the reference nucleic acid sequence. Such variants include sequences that are shorter or longer than the reference nucleic acid sequence, sequences that have different residues at specific positions, or combinations thereof.

[0030] The term "adjuvant" refers to a substance or vehicle that nonspecifically enhances the immune response to an antigen. Adjuvants can include suspensions of minerals (alum, aluminum hydroxide, or phosphate) to which antigens are adsorbed; or water-in-oil emulsions in which antigen solutions are emulsified in mineral oil (e.g., Freund's incomplete adjuvant), which may also include killed mycobacteria to further enhance antigenicity (Freund's complete adjuvant). Immunostimulatory oligonucleotides can also be used as adjuvants (see, for example, U.S. Patent Nos. 6,194,388; 6,207,646; 6,214,806; 6,218,371; 6,239,116; 6,339,068; 6,406,705; and 6,429,199). Adjuvants also include biological molecules, such as costimulatory molecules.

[0031] The term "administration" refers to a method of providing a substance, such as a therapeutic agent, to a subject by any effective route. Examples of administration routes include, but are not limited to, injection (subcutaneous, intramuscular, intradermal, intraperitoneal, intravenous, etc.), oral, intraductal, sublingual, rectal, transdermal, intranasal, vaginal, and inhalation routes.

[0032] The terms "coding sequence" and "coding region" as used herein refer to nucleotide and nucleic acid sequences (including both RNA and DNA) that encode the genetic information for the synthesis of RNA, protein, or any portion of RNA or protein.

[0033] The term "effective amount" of the composition provided herein refers to the amount of the composition that can perform the specific function for which the effective amount is expressed. The exact amount required may vary from composition to composition and from function to function, depending on recognized variables such as the composition and process involved. An effective amount may be delivered in one or more applications. Thus, it is not possible to specify an exact amount, but a suitable "effective amount" can be determined by those skilled in the art through routine experimentation.

[0034] The terms "I177L", "ASFV I177L", and "genomic I177L" are synonymous and refer to the gene defined herein as SEQ ID NO:3, or any version of SEQ ID NO:3 with base substitutions that result in a protein having the same sequence as SEQ ID NO:4. These terms may also refer, in the appropriate context, to modified versions of these SEQ ID NOs, such as those containing deletions, insertions, and other recombinant modifications. The open reading frame I177L of ASFV-G encodes a 177 amino acid protein (SEQ ID NO:4) and is located on the reverse strand between nucleotide positions 174471 and 175004 of SEQ ID NO:1.

[0035] In the context of the present invention, the term "non-functional genomic I177L" refers to a modified I177L gene located in the genome of ASFV, such modification of the ASFV I177L gene resulting in no ASFV I177L gene product or a biologically non-functional ASFV I177L gene product compared to the unmodified functional ASFV I177L gene. Such modifications include, but are not limited to, complete or partial deletion of coding sequences, disruption of the open reading frame (e.g., insertion of a shift mutation or insertion of a nonsense codon), modification of upstream or downstream regulatory elements, and / or other currently known or contemplated methods of inactivating or knocking out the functional expression of such an ASFV I177L gene.

[0036] The term "immunize" means to protect a subject against an infectious disease, such as by vaccination.

[0037] For the purposes of the present invention, the "sequence identity" of two related nucleotide or amino acid sequences, expressed as a percentage, represents the number of positions with identical residues in two optimally aligned sequences (x 100), divided by the number of positions compared. Gaps, i.e. positions in the alignment where a residue is present in one sequence but not in the other, are considered to be positions with non-identical residues. The alignment of two sequences is performed by the Needleman and Wunsch algorithm (Needleman and Wunsch, J Mol Biol, (1970) 48:3, 443-53). Computer-assisted sequence alignment can be conveniently performed using standard software programs such as, for example, GAP (using the default scoring matrix with a gap creation penalty of 50 and a gap extension penalty of 3), which is part of the Wisconsin Package Version 10.1 (Genetics Computer Group, Madison, Wisconsin, USA).

[0038] The phrases "high percent identical" or "high percent identity" in the context of two polynucleotides or polypeptides, and grammatical variations thereof, refer to two or more sequences or subsequences that have at least about 80% identity, at least about 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% nucleotide or amino acid identity when compared and aligned for maximum correspondence, as measured using a sequence comparison algorithm or by visual inspection. In one exemplary embodiment, the sequences are high percent identical over the entire length of the polynucleotide or polypeptide sequence.

[0039] The term "pig" can refer generally to any member of the family Suidae, including domestic and wild pigs, hogs, and boars.

[0040] A "vaccine" is defined herein as a biological agent capable of providing a protective response in animals to which it is delivered, but unable to cause severe disease. Administration of the vaccine results in immunity against disease. Thus, the vaccine stimulates antibody production or cellular immunity against disease-causing pathogens (e.g., ASFV). Immunity is defined herein as the induction of a significantly higher level of protection against lethality and clinical symptoms following vaccination in pig populations compared to non-vaccinated groups. In particular, the vaccine according to the present invention protects a majority of vaccinated animals from developing clinical symptoms and lethality of the disease. The vaccines of the present disclosure are typically genetically engineered (recombinant) mutant virus vaccines.

[0041] In the context of the present disclosure, the term "non-replication defective" refers to a non-naturally occurring recombinant ASFV that is capable of replicating and / or producing viral progeny in vitro and / or in vivo (although such replication and / or viral progeny production may also occur at reduced levels compared to the unmodified parental strain). Thus, such an ASFV may be non-replication defective in vitro (e.g., in cell culture), but at least partially replication defective in vivo in a mammal, e.g., resulting in replication and / or viral progeny production below detectable limits.

[0042] As used herein, the term "minimum dose" or "minimum effective dose" refers to a dose that exhibits an absence or minimal presence of toxicity to the recipient, yet results in the production of a desired result (e.g., protective immunity).

[0043] Viruses / Vaccines

[0044] Provided herein is a novel mutant ASFV-GΔI177L virus (SEQ ID NO:2) resulting from a recombinant deletion of a portion of the I177L gene (SEQ ID NO:3) of the parent ASFV-G genome (SEQ ID NO:1). The genomic nucleotide sequence of the particular recombinant mutant ASFV-GΔI177L (SEQ ID NO:2) is described herein, which differs from the genomic nucleotide sequence encoding the parent ASFV-G (SEQ ID NO:1). The 177 amino acid protein encoded by ASFV-G I177L (SEQ ID NO:4) differs from the predicted mutant I177L protein encoded by the mutant nucleotide sequence of ASFV-GΔI177L. The I177L protein from ASFV-GΔI177L (SEQ ID NO:6) is predicted to lack amino acids 112 to 150 of the wild-type I177L protein. Because the p72Mcherry cassette is inserted at this position (see the Examples section), the coding region remaining after this insertion is not expected to be transcribed and, as a result, no functional I177L protein is produced upon viral infection.

[0045] The exemplary mutant strain (ASFV-GΔI177L (SEQ ID NO:2)) represents a genus of recombinant vaccines in which the ASFV I177L gene has been rendered non-functional, including but not limited to deletion mutants, nonsense mutants, insertion mutants, frameshift mutants, and other mutants that result in no expression of the I177L protein or expression of a non-functional I177L protein. Other recombinant viruses contemplated include mutants of regulatory elements that result in no expression or no translation of the I177L protein.

[0046] Modifications intended to eliminate functional expression of a target protein (e.g., I177L) or to reduce expression or activity of a target protein may involve mutations in the DNA or gene encoding the target protein, including deletions of all or part of the target gene (including, but not limited to, the open reading frame of the target locus, transcriptional regulators such as the promoter of the target locus, and other regulatory nucleic acid sequences located 5' or 3' of the open reading frame), insertions of premature stop codons into the open reading frame, and insertions or deletions that shift the reading frame and result in premature termination of translation. Such deletion mutations can be achieved using any technique known to those of skill in the art. Reduced levels of a target protein or reduced activity of a target protein can also be achieved by point mutations or insertions in the DNA or gene encoding the target protein. Mutational, insertional, and deletional variants of the disclosed nucleotide sequences and genes can be readily prepared by methods well known to those of skill in the art. Techniques used to achieve reduced levels and / or reduced activity of a target protein may include CRISPR / Cas, TALEN, and Zn finger nucleases. It is well within the skill of one in the art to make mutations, insertions, and deletions that are functionally equivalent to the specific ones disclosed herein.

[0047] The approach described herein used to generate deletion mutants of I117L in ASFV-G can be used in different isolates of ASFV where functional I117L is present (such as isolates distributed in Asia, Europe, or Africa). Such approaches can be modified by methods known in the art, for example, different selection markers can be used to select recombinant viruses by purification, such as, but not limited to, fluorescent proteins, enzymes such as beta-glucuronidase or beta-galactosidase that can be used with chromogenic substrates, and drug selection markers. Such approaches can also be used to generate any mutations in the ORF of I177L, as well as mutations in regulatory elements that control the expression and translation of the I177L gene that result in a non-functional I177L protein.

[0048] Mutants of I177L (and related strain-specific alleles) in other ASFV strains and genotypes are also encompassed by the present disclosure. ASFV strains that contain synthetic mutations in nucleic acid sequences that exhibit at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO:3 are encompassed by the present invention. ASFV strains that contain a whole genome with 95%, 96%, 97%, 98%, 99% or more identity to SEQ ID NO:2 are also encompassed by the present invention.

[0049] The present disclosure further contemplates the combination of a non-functional I177L gene with other recombinant mutations. Thus, not only wild-type viruses can be modified as disclosed herein, but also strains containing non-naturally occurring mutations in other genes or genomic regions (see, e.g., U.S. Patent No. 9,814,771).

[0050] The present disclosure provides that such rationally designed, live attenuated ASFV-GΔI177L can be incorporated into an immunogenic composition to produce an effective vaccine to protect animals, such as pigs, from clinical ASF disease when challenged with ASFV-G. Accordingly, one object of the present invention is to provide a method of protecting animals from ASFV-G by administering an effective amount of a rationally designed live attenuated ASFV-GΔI177L vaccine. In another embodiment, the present disclosure provides a method for eliciting a protective immune response in animals, preferably of the family Suidae (e.g., domestic pig (Sus scrofa domesticus), wild pig (Sus scrofa scrofa), warthog (Potamochoerus porcus), bush pig (Potamochoerus larvatus), forest pig (Hylochoerus meinertzhageni), and feral pig). Such methods typically involve administering to such animals one or more of the ASFV immunogenic compositions and vaccines described herein.

[0051] A further object of the present disclosure is to provide a method for distinguishing animals infected with wild-type ASFV from animals vaccinated with the recombinant virus described herein. Such a methodology for distinguishing infected from vaccinated animals (DIVA) can be achieved by serological tests that detect differences between wild-type and mutant I177L proteins. Alternatively, such methodologies may include genetic screening approaches, such as those based on PCR amplification and detection of different products. Typically, such approaches utilize one or more primer sets that extend the same region adjacent to the mutation site, resulting in products of different lengths or sequences.

[0052] The immunogenic composition(s) of the present invention comprises a recombinant ASFV having a non-functional I177L gene / protein, regardless of other components contained therein. The I177L protein of the present invention may comprise the entirety of SEQ ID NO:4 and a protein having 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identity to the protein of SEQ ID NO:4.

[0053] The immunogenically effective amount of the immunogenic compositions disclosed herein may vary based on several parameters. However, in general, the effective amount per dosage unit for intramuscular administration is about 10 2 50% hemoadsorption (HAD 50 ")~10 6 HAD 50 One, two or more dosage units may be utilized in carrying out the method of the present invention. The dosage unit may be easily modified by those skilled in the art to fit the desired volume or mass. Regardless of dosage unit parameters, the immunogenic compositions disclosed herein may be administered in an amount effective to generate an immune response.

[0054] The dosage level of the active ingredient in the vaccine disclosed herein can be varied by those skilled in the art to achieve the desired results in a subject or for each application.As such, the selected dosage level can depend on various factors, including but not limited to, formulation, combination with other treatments, severity of pre-existing conditions, and the presence or absence of adjuvants.In a preferred embodiment, a minimum dose of the immunogenic composition is administered.The determination of the minimum dose is well within the capabilities of those skilled in the art.

[0055] The vaccine of the present invention can be prepared by conventional methods used for commercially available live attenuated ASFV vaccines. In a particular embodiment, a susceptible substrate is inoculated with the ASFV-GΔI177L mutant and allowed to grow until the virus replicates to a desired titer, after which the ASFV-GΔI177L-containing material is harvested. Following this, the harvested material can be formulated into a vaccine preparation with immunogenic properties. Any substrate capable of supporting the replication of the recombinant viruses provided herein can be used in the present invention, including primary cultures of porcine peripheral blood macrophages or blood from infected pigs.

[0056] Formulation and Administration

[0057] The vaccine provided herein comprises one of the recombinant viruses defined above in live form and a pharmacy acceptable carrier or diluent that is conventionally used for such compositions. Carriers include stabilizers, preservatives and buffers. Suitable stabilizers include, for example, SPGA (sucrose, phosphate, glutamate, and albumin), carbohydrates (sorbitol, mannitol, starch, sucrose, dextran, glutamate, and glucose), proteins (dry milk, serum, albumin, casein), or their degradation products. Suitable buffers include, for example, alkali metal phosphates. Applicable preservatives include, but are not limited to, thimerosal, merthiolate, and gentamicin. Diluents include water, aqueous buffers (e.g., buffered saline), alcohols, and polyols (e.g., glycerol).

[0058] In some instances, the vaccines of the present invention also contain or include one or more adjuvants, which include any substance included in the immunogenic composition formulation that enhances the immune response in the recipient induced by the immunogenic composition. In some cases, such adjuvants may include proteins, other components included with the recombinant virus. Other adjuvants can be included as additional components of the immunogenic composition, including categories such as aluminum salts (alum), oil emulsions, saponins, immune stimulating complexes (ISCOMs), liposomes, microparticles, non-ionic block copolymers, derivatized polysaccharides, cytokines, and a wide range of bacterial derivatives. Any relevant adjuvant known in the art can be utilized in practicing the invention disclosed herein. Factors influencing the choice of adjuvant include the animal species, the specific pathogen, the antigen, the route of immunization, and the type of immunity required, and can be easily determined by one of skill in the art.

[0059] The immunogenic composition of the present disclosure can also include a carrier in addition to recombinant virus. The carrier utilized in carrying out the immunogenic composition provided herein can be any known in the art, and can be liquid, solid, semi-solid or gel. The type of formulation can be changed according to the route of administration of the antigen. Preferably, the carrier is non-toxic to the recipient. Those skilled in the art can easily select such carriers for application to recipient animals such as poultry.

[0060] The present disclosure provides immunogenic compositions for introducing recombinant ASFV lacking a functional I177L gene / protein into a target (e.g., a pig) in a composition comprising at least the recombinant virus. Thus, the compositions provided herein can be utilized to induce immunity or resistance to ASFV disease.

[0061] The vaccines provided herein may be administered intramuscularly, subcutaneously, intranasally, or by injection in an amount effective to protect animals from challenge with virulent strains of ASFV. The vaccines may be administered orally, by direct oral inoculation, in drinking water, or via a bait delivery system. The effective amount of the recombinant virus may vary according to parameters considered by the skilled artisan. The effective amount may be determined experimentally, if necessary, by the skilled artisan following known methods or guidance provided in the examples herein.

[0062] Having generally described the invention, it will be better understood by reference to specific examples, which are included herein to further illustrate the invention and are not intended to limit the scope of the invention, which is defined by the claims. EXAMPLES

[0063] [Example 1]

[0064] Cell cultures and viruses.

[0065] Primary porcine macrophage cell cultures were prepared from defibrinated porcine blood as previously described (Zsak et al, J.Virol., (1998) 72:1028-35). Briefly, heparinized porcine blood was incubated at 37°C for 1 hour and the red blood cell fraction was sedimented. Mononuclear leukocytes were separated (specific gravity 1.079) by flotation on a Ficoll-Paque (Pharmacia, Piscataway, NJ) density gradient. The monocyte / macrophage cell fraction was cultured for 48 hours at 37°C under 5% CO2 in plastic Primaria (Falcon; Becton Dickinson Labware, Franklin Lakes, NJ) tissue culture flasks containing macrophage medium consisting of RPMI 1640 medium (Life Technologies, Grand Island, NY) with 30% L929 supernatant and 20% fetal bovine serum (HI-FBS, Thermo Scientific, Waltham, MA). Adherent cells were detached from the plastic using 10 mM EDTA in phosphate-buffered saline (PBS) and then cultured at 5 × 10 for use in the assay 24 h later. 6 The cells were replated into Primaria T25, 6, or 96-well dishes at a density of 1000 cells / ml.

[0066] Virus titration was performed using primary cultures of porcine macrophage cells in 96-well plates. Virus dilution and incubation were performed in macrophage medium. The presence of virus was assessed by hemadsorption (HA), and virus titers were calculated by the method of Reed and Muench (Amer. J. Hygiene, (1938) 27:493-497).

[0067] The ASFV Georgia (ASFV‐G) used in this study was a field isolate kindly provided by Dr. Nino Vepkhvadze at the Laboratory of the Ministry of Agriculture (LMA), Tbilisi, Republic of Georgia.

[0068] [Example 2]

[0069] Construction of recombinant ASFV-GΔI177L

[0070] Recombinant ASFV was generated by sequential homologous recombination between the parental ASFV genome and a recombinant transfer vector in an infection and transfection procedure using porcine macrophage cell cultures (Neilan et al, Virol., (2004) 319:337-42; Zsak et al, supra). A recombinant transfer vector (p72GUSΔI177L) was used that contains flanking genomic regions mapping to the left (1 kbp) and right (1 kbp) of the gene and including part of I177L, and a reporter gene cassette, p72mCherry, containing the mCherry gene with the ASFV p72 late gene promoter. This construct created a 112-nucleotide deletion in the I177L ORF (amino acid residues 112 to 150) (Figure 1). The recombinant transfer vector p72mCherryΔI177L was obtained by DNA synthesis (Epoch Biosciences, Bothwell, WA, USA). Macrophage cell cultures were infected with ASFV-G and transfected with p72mCherryΔI177L. Recombinant viruses representing independent primary plaques were purified to homogeneity by successive rounds of plaque assay purification. Recombinant viruses were obtained after 14 consecutive plaque purification events on monolayers of primary porcine macrophage cell cultures.

[0071] [Example 3]

[0072] Whole genome sequence analysis of ASFV-GΔI177L compared with the parental ASFV-G.

[0073] To assess the accuracy of the genetic recombination and the genomic integrity of the recombinant virus, the whole genome sequences of ASFV-GΔI177L and the parental ASFV-G were obtained and compared using next-generation sequencing (NGS). As a first step, a full-length genome comparison was performed between the parental ASFV-G laboratory strain used to construct the ASFV-GΔI177L mutant virus and the original ASFV Georgia 2007 / 1 (Chapman et al, Emerg. Infect. Dis., (2001) 17:599-605; GenBank accession FR682468). ASFV DNA was obtained from the cytoplasm of infected cells using the Trizol method (Life Technologies, Grand Island, NY, USA). DNA concentration was measured using the Qubit® dsDNA HS Assay Kit (Life Technologies) and read on a Qubit® 2 Fluorometer (Life Technologies). Briefly, viral DNA was sheared using an enzymatic reaction that was evaluated for size fragmentation distribution, and then ligation of identification barcodes using adapter sequences was added to the DNA fragments. The required size range of the library was collected and normalized using Pippin Prep™ (Sage Science, Beverly, MA). The DNA library was then used for NGS sequencing using NextSeq (Illumnia, San Diego, CA) according to the manufacturer's protocol. Sequence analysis was performed using CLC Genomics Workbench software (CLC Bio, Waltham, MA).

[0074] The following differences were observed between these two viruses (nucleotide positions are provided based on ASFV Georgia 2007 / 1, GenBank accession FR682468?): (i) three nucleotide insertions, namely a T at position 433, an A at position 441 in the non-coding region of the genome, and an A at position 174954 in the I177L gene, which merges I177L with the ORF ASFV_G_ACD_01760, but this additional nucleotide makes the ORF I117L similar to a full-length gene as in other isolates, since with the additional A there is no premature stop codon and no out-of-frame mutation as described in the reference genome; (ii) a two-nucleotide deletion, namely a T at position 1602 and a T at position 1603 in the MGF 360-1L gene ORF, which results in a frameshift; (iii) a single nucleotide deletion, namely a T at position 1602 and a T at position 1603 in the MGF 360-1L gene ORF, which results in a frameshift; (iv) a single nucleotide change, A → G at position 97391 resulting in a silent mutation in ORF B438L; (v) a single nucleotide change, C → G at position 166192 resulting in a residue substitution (Ala to Pro) at residue position 85 of ORF E199L; and (vi) a nucleotide insertion at position 183303, a non-coding segment of the genome.

[0075] To determine whether the recombinant virus acquired additional genetic changes from the parental strain, a full-length genome comparison between ASFV-GΔI177L and the parental strain ASFV-G was performed. DNA sequence assembly of ASFV-GΔI177L and ASFV-G revealed a 112-nucleotide deletion in the I177L gene corresponding to the introduced modification. The consensus sequence of the ASFV-GΔI177l genome showed an insertion of 3944 nucleotides in the I177L gene, corresponding to the p72-mcherry cassette sequence introduced to generate the 112-nucleotide deletion in the target gene. Besides the insertion of the cassette, no additional differences were observed between the genomes of ASFV-GΔI177l and ASFV-G. In summary, the ASFV-GΔI177l virus did not accumulate significant mutations during the process of homologous recombination and plaque purification.

[0076] [Example 4]

[0077] Evaluation of ASFV-G.DELTA.I177L pathogenicity in pigs

[0078] Animal experiments were performed under biosafety level 3 conditions in the animal facility of the PIADC according to protocols approved by the Institutional Animal Care and Use Committee.

[0079] A commercial breeding pig weighing 80-90 lbs was used to evaluate the pathogenic phenotype of ASFV-GΔI177L compared to the virulent parent ASFV-G virus. Five pigs were cultured for 10 min. 2 , 10 4 , 10 6 HAD 50 ASFV‐GΔI177L or 10 2 HAD 50 The animals were inoculated intramuscularly (IM) with 100 mg of ASFV-G virus. Clinical signs (anorexia, depression, fever, purple skin discoloration, staggering gait, diarrhea, and coughing) and changes in body temperature were recorded daily throughout the experimental period. 2 , 10 4 , 10 6 HAD 50 The mice were inoculated IM with ASFV-GΔI177L and 28 days later,2 HAD 50 The mice were challenged IM with the virulent parental ASFV-Georgia 2007 strain of ASFV. The presence of disease-associated clinical signs was assessed as previously described.

[0080] 10 4 HAD 50 All pigs inoculated IM with ASFV-G showed elevated body temperatures (>104°F) by 3-4 days post-infection. The pigs exhibited clinical signs associated with the disease, including anorexia, depression, purple skin discoloration, stumbling gait, and diarrhea (Table 1). Signs of disease progressively worsened over time, and by 7 or 9 days post-infection, the animals had died or were ultimately euthanized. Conversely, 10 2 , 10 4 , or 10 6 HAD 50 Animals inoculated IM with ASFV-GΔI177L showed no signs of clinical disease during the entire observation period (21 days). Thus, deletion of the I177L gene resulted in complete attenuation of the virulent parental ASFV-G. All animals in the mock-vaccinated group were euthanized for humane reasons according to the corresponding IACUC protocol. Table 1:10 2 HAD 50 Survival and fever response of pigs following infection with doses of ASFV-G-ΔI177L or parental ASFV-G. [Table 1]

[0081] Animals infected with ASFV-G produced the expected high homogenous titers on day 4 p.i. (10 7.5 ~10 8.5 HAD 50 / ml), which increased by 7 days p.i. (approximately 10 8.5 HAD 50 Conversely, ASFV-G-ΔI177L induced low viremia (10 1.8 ~10 2.3 HAD 50 / ml), reaching a peak value by day 11 pi (10 3.8 ~10 7.5 HAD 50 / ml), followed by a decrease in titer until day 28 p.i. (10 2.3 ~10 4 HAD 50 The results showed a distinct pattern of viremia, with 1 animal inoculated with ASFV-G-ΔI177L exhibiting a significantly lower viremia than the mean viremia values ​​of the other animals in the group (1,000- to 10,000-fold lower, depending on the time point of evaluation). Thus, deletion of the I177L gene resulted in a complete attenuation of the parent ASFV-G virus, which is highly pathogenic when inoculated at low doses, and infected animals showed a prolonged viremia at relatively low levels.

[0082] [Example 5]

[0083] Protective effect of ASFV-GΔI177L against challenge with parental ASFV-G.

[0084] 10 2 HAD 50 ~10 6 HAD 50 Pigs inoculated IM with 10% ASFV-GΔI177L survived the infection without signs of disease. 2 HAD 50 ~10 6 HAD 50 Groups of animals (n=5) inoculated with ASFV-GΔI177L were cultured at 10 dpi on day 28 p.i. 2 HAD 50 All animals were challenged via IM with the parental ASFV-G of 1000 ng / mL (homologous challenge). Five naïve animals challenged by the same route and dose served as non-vaccinated / challenged controls. All animals were 2 HAD 50 Vaccination with ASFV-GΔI177L was performed IM and 28 days later, 10 2 HAD 50All animals in the mock-vaccinated group were euthanized for humane reasons according to the corresponding IACUC protocol. All animals in the ASFV-GΔI177L-vaccinated group remained clinically normal during the 21-day observation period after challenge.

[0085] The five animals inoculated and challenged with ASFV-GΔI177L remained completely asymptomatic during the entire observation period (21 days) (Table 2). All animals in the mock-vaccinated / challenged control group showed no symptoms within 10 days. 2 HAD 50 All animals inoculated with ASFV-G developed a clinical course of disease similar to that observed in animals inoculated with ASFV-G (see above). Thus, ASFV-GΔI177L is able to induce protection against developing clinical disease when challenged with the highly virulent parent virus. Table 2: Survival rate and fever response in pigs challenged with ASFV-G virus on day 28 post-ASFV-G-ΔI177L infection. [Table 2]

[0086] Analysis of viremia in animals infected with ASFV-G showed the expected high titers (10 7.3 ~10 8.3 HAD 50 / ml), which increased by 7 days pi (average 10 8.5 HAD 50 All animals (< 0.05 mg / ml) were euthanized. After challenge, no ASFV-G-ΔI177L-infected animals exhibited viremia at levels higher than that present at the time of challenge, and viremia levels tapered off until the end of the experimental period (day 21 post-challenge), at which time, importantly, no circulating virus was detectable in the blood of any of these animals (Fig. 5).

[0087] In summary, we present here evidence that deletion of the I177L gene dramatically altered the pathogenicity of ASFV-G, producing a fully attenuated virus, designated ASFV-GΔI177L. Animals immunized with ASFV-GΔI177L were protected against challenge with the pathogenic parental ASFV-G.

[0088] [Example 6]

[0089] Replication of ASFV-G-I117L in porcine macrophages

[0090] Using primary cultures of porcine macrophage cells, the main cells targeted by ASFV during porcine infection, the in vitro growth characteristics of ASFV-G-ΔI177L were evaluated and compared to the parental ASFV-G in a multi-step growth curve (Figure 2). Cell cultures were infected at an MOI of 0.01 and samples were collected at 2, 24, 48, 72 and 96 hours post-infection (hpi). Results showed that ASFV-G-ΔI177L exhibited significantly reduced growth kinetics compared to the parental ASFV-G. Yields of ASFV-G-ΔI177L were approximately 100- to 1,000-fold lower than ASFV-G depending on the time point evaluated.

[0091] Thus, deletion of the I177L gene significantly reduced the ability of ASFV-G-ΔI177L to replicate in vitro in primary porcine macrophage cell cultures compared with the parental ASFV-G isolate.

[0092] [Example 7]

[0093] ASFV-G-ΔI117L-infected animals do not shed vaccine virus

[0094] Five pigs from different groups were 2 , 10 4 , or 10 6 HAD 50In the above examples, where animals were infected IM with ASFV-GΔI177L, mock-infected animals were co-present in each group as sentinels to detect virus that may be shed by the infected animals. All sentinel animals remained clinically normal (Figure 4). No virus was detected in any of the samples obtained from the sentinel animals (all blood collection time points and tonsil and spleen samples obtained on day 28 pi), indicating that ASFV-G-ΔI177L-infected animals were not able to shed sufficient virus to infect naive pigs during the relatively long co-culture period of 28 days.

[0095] In summary, non-vaccinated animals kept in the presence of vaccinated animals for 28 days did not show any clinical signs and all blood, tonsil and spleen samples taken were negative for the vaccine virus, indicating that the vaccine virus cannot be shed into non-vaccinated animals.

[0096] [Example 8]

[0097] Host antibody responses in animals infected with ASFV-G-ΔI177L

[0098] All animals infected with ASFV-G-ΔI177L had similarly high circulating anti-ASFV antibody titers, regardless of the administered virus dose (Fig. 6). Antibody responses mediated by IgM and IgG isotypes start to be detected in all three groups by day 12 pi. By day 14 pi, responses mediated by both antibody isotypes reached maximum levels in all groups. IgM-mediated antibody responses disappeared in all animals by day 21 pi, whereas IgG-mediated responses remained high with minimal fluctuations until day 28 pi and did not differ significantly among the three groups of animals inoculated with ASFV-G-ΔI177L. Thus, there is a close correlation between the presence of anti-ASFV antibodies at the time of challenge and protection. It should be noted that in serum samples obtained from sentinel animals, 10 6 HAD 50It should be mentioned that no antibodies were detected except for a low antibody titer observed in one sample 28 days after infection with ASFV in the group receiving G-ΔI177L.

[0099] [Example 9]

[0100] Induction of sterile immunity

[0101] To specifically detect only the challenge virus, I177L-specific real-time PCR (approximately 10 HAD 50 Using a PCR assay (which allows for the detection of IgG1, IgG2, and IgG3) all blood samples tested were negative for the presence of challenge virus. In addition, tonsil and spleen samples were taken from all animals at the end of the observation period (day 21 post-challenge) and tested for the presence of virus by virus isolation in porcine macrophage cultures. Most animals in each group showed the presence of infectious virus in either the tonsils or spleen (data not shown). All positive samples were then evaluated using an I177L-specific real-time PCR, with an initial 10 2 HAD 50 We detected the presence of challenge virus in only one spleen belonging to one of the animals that had been infected with 10 / ml ASFV-G-ΔI177L. 4 HAD 50 All infected animals receiving ≥ 10 2 HAD 50 These results suggest that challenge virus replication was absent in the majority of animals receiving 100 / ml ASFV-G-ΔI177L.

[0102] In summary, 10 2 HAD 50 Partial sterile immunity (immunity that does not allow replication of the challenge virus) was achieved in animals vaccinated with 10 4 HAD 50 / ml or 10 6 HAD 50 / ml dose of ASFV-G-ΔI177L was fully achieved.

[0103] The present disclosure includes the following embodiments. EMBODIMENT 1 A genetically modified virus, comprising a viral genome that is at least 99% identical to SEQ ID NO:2. EMBODIMENT 2 The virus of embodiment 1, wherein the viral genome comprises SEQ ID NO:2. EMBODIMENT 3 A vaccine composition against African swine fever virus (ASFV) comprising a genetically modified virus as described in embodiment 1. EMBODIMENT 4 The vaccine composition of embodiment 3, wherein the ASFV is ASFV-Georgia 2007 isolate (ASFV-G). EMBODIMENT 5 13. A method for protecting pigs against ASFV, comprising administering to the pig a live attenuated vaccine comprising the genetically modified virus of embodiment 1 in an amount effective to protect the pig from clinical ASFV disease. EMBODIMENT 6 The method of embodiment 5, wherein the ASFV is ASFV-G. EMBODIMENT 7 The amount effective to protect said pigs from clinical ASFV disease is 10 2 ~10 6 HAD 50 The method according to embodiment 5, wherein the vaccine comprises the genetically modified virus according to embodiment 1. EMBODIMENT 8 A recombinant ASFV mutant virus, comprising a synthetic mutation in the I177L open reading frame or in a regulatory element controlling expression of the I177L protein, resulting in a non-functional genomic I177L gene. EMBODIMENT 9 The recombinant virus of embodiment 8, wherein the synthetic mutation is a deletion mutation resulting in a deletion of one or more nucleotides from position 174471 to position 175004 of SEQ ID NO:1. EMBODIMENT 10 The recombinant virus of embodiment 8, wherein the synthetic mutation is a frameshift mutation, an insertion mutation, or a nonsense mutation of one or more nucleotides from position 174471 to position 175004 of SEQ ID NO:1. EMBODIMENT 11 The recombinant virus of embodiment 8, wherein the mutant ASFV is an ASFV-Georgia isolate. EMBODIMENT 12 The recombinant virus of embodiment 8, wherein the mutant ASFV comprises a genome that is at least 95% identical to SEQ ID NO:2. EMBODIMENT 13 The recombinant virus of embodiment 8, wherein the mutant ASFV comprises a genome that is at least 99% identical to SEQ ID NO:2. EMBODIMENT 14 A vaccine composition against ASFV-G comprising a recombinant virus as described in embodiment 8. EMBODIMENT 15 10. A method for protecting pigs against ASFV, comprising administering to the pig a live attenuated vaccine comprising the recombinant virus of embodiment 8 in an amount effective to protect the pig from clinical ASFV disease. EMBODIMENT 16 The method of embodiment 14, wherein the ASFV is ASFV-G. EMBODIMENT 17 The amount effective to protect said pigs from clinical ASFV disease is 102 ~10 6 HAD 50 The method according to embodiment 14, wherein the vaccine comprises the genetically modified virus according to embodiment 8. Although the invention has been described with reference to details of the illustrated embodiments, these details are not intended to limit the scope of the invention, which is defined in the appended claims. The embodiments of the present disclosure in which an exclusive property or privilege is claimed are defined in the claims.

Claims

1. 1. A genetically modified virus, comprising a viral genome that is at least 99% identical to SEQ ID NO:2, wherein said viral genome lacks a sequence corresponding to positions 174560 to 174671 of SEQ ID NO:

1.

2. The virus of claim 1 , wherein the viral genome comprises SEQ ID NO:

2.

3. A vaccine composition against African swine fever virus (ASFV), comprising the genetically modified virus of claim 1.

4. The vaccine composition of claim 3, wherein the ASFV is the ASFV-Georgia 2007 isolate (ASFV-G).

5. 11. A method for protecting pigs from ASFV, comprising administering to the pig a live attenuated vaccine comprising the genetically modified virus of claim 1 in an amount effective to protect the pig from clinical ASFV disease.

6. The method of claim 5, wherein the ASFV is ASFV-G.

7. The amount effective to protect said pigs from clinical ASFV disease is 10 2 ~10 6 HAD 50 The method according to claim 5, which is a vaccine comprising the genetically modified virus of claim 1.

8. A recombinant ASFV mutant virus, comprising a synthetic mutation in the I177L open reading frame or in a regulatory element controlling expression of the I177L protein, resulting in a non-functional genomic I177L gene.

9. The recombinant virus of claim 8, wherein the synthetic mutation is a deletion mutation resulting in a deletion of one or more nucleotides from position 174471 to position 175004 of SEQ ID NO:

1.

10. The recombinant virus of claim 8, wherein the synthetic mutation is a frameshift mutation, an insertion mutation, or a nonsense mutation of one or more nucleotides from position 174471 to position 175004 of SEQ ID NO:

1.

11. The recombinant virus of claim 8 , wherein the mutant ASFV is an ASFV-Georgia isolate.

12. The recombinant virus of claim 8, wherein the mutant ASFV comprises a genome that is at least 95% identical to SEQ ID NO:

2.

13. The recombinant virus of claim 8, wherein the mutant ASFV comprises a genome that is at least 99% identical to SEQ ID NO:

2.

14. A vaccine composition against ASFV-G, comprising the recombinant virus of claim 8.

15. 10. A method for protecting pigs against ASFV, comprising administering to the pig a live attenuated vaccine comprising the recombinant virus of claim 8 in an amount effective to protect the pig from clinical ASFV disease.

16. The method of claim 14, wherein the ASFV is ASFV-G.

17. The amount effective to protect said pigs from clinical ASFV disease is 10 2 ~10 6 HAD 50 The method according to claim 14, which is a vaccine comprising the genetically modified virus of claim 8.

Citation Information

Patent Citations

  • Rationally developed attenuated African swine fever virus strains protect against challenge with the parental virus of the Georgia 2007 isolate

    JP2019520827A